Table of Contents
VAUGHAN, Ontario — Bausch + Lomb Corp. announced that Health Canada has approved Lumify (brimonidine tartrate ophthalmic solution 0.025% w/v), the first and only over-the-counter eye drop developed with low-dose brimonidine tartrate to relieve redness of the eye due to minor eye irritations for adults.
“With Health Canada’s approval of LUMIFY, we are excited to be able to now offer Canadians a new option to help relieve their red, irritated eyes,” said Joe Gordon, president, Global Consumer, Surgical and Vision Care. “Bausch + Lomb is dedicated to meeting the needs of eye care professionals and their patients, and we’re proud to bring Lumify forward as an example of our continued commitment to developing innovative eye health products.”
Eye redness occurs as a result of minor eye irritations such as environmental allergies, dryness and fatigue. Lumify works by selectively targeting redness and thereby reducing the potential for side effects such as rebound redness and tachyphylaxis.1 In clinical trials, Lumify eye drops demonstrated significant reduction in ocular redness seen as early as one minute and persisted up to eight hours.1 An in-home-use-study with over 300 participants also resulted in a 95% satisfaction rating for the product.2
“Ocular redness is often one of the first things people notice when making eye contact. It can affect daily life and have a negative social impact, especially for important occasions such as critical meetings or events,” said Riyad Khamis, O.D., FAAO, FCOVD, London, Ontario. “I look forward to offering my patients LUMIFY so they can quickly reduce their eye redness due to minor eye irritations while reducing concerns of rebound hyperemia, which can lead to corneal issues.”
Lumify is expected to be available at all major pharmacy retailers in Canada by July 2022 in both 3.5 mL and 7.5 mL size formats.
Lumify was approved by the U.S. Food and Drug Administration in the United States in 2017. Since then, Lumify has been honored with more than 10 awards, including being named to IRI’s 2019 New Product Pacesetters 25th annual report and BASES, a Nielsen Global Consumer business division, 2020 U.S. BASES Top 25 Breakthrough Innovations Listin the “Superstar” category
